Fredun Pharmaceuticals Ltd

With a decisive surge to Rs 2680 on 17 Jun 2026, Fredun Pharmaceuticals Ltd has reached a new 52-week and all-time high, marking a remarkable rally from its low of Rs 791 just a year ago. This milestone caps a sustained period of strong price momentum, supported by a confluence of bullish technical indicators across multiple timeframes.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of ₹2,649 on 17 June 2026, reflecting a robust performance trajectory in the Pharmaceuticals & Biotechnology sector. This achievement underscores the company’s sustained growth and strong market positioning over recent years.

Fredun Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 June 2026, providing investors with the latest insights into its performance and outlook.

Fredun Pharmaceuticals Ltd has been upgraded from a Hold to a Buy rating following a comprehensive reassessment of its financial performance, valuation metrics, quality indicators, and technical outlook. The micro-cap pharmaceutical company’s recent quarterly results, improved valuation multiples, and sustained operational momentum have collectively driven this positive revision in its investment grade.

Fredun Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 May 2026, providing investors with the latest insights into its performance and outlook.

Fredun Pharmaceuticals Ltd has undergone a notable shift in its valuation parameters, moving from an expensive to an attractive price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positions the micro-cap pharmaceutical company as a compelling consideration within its sector amid robust returns and improving fundamentals.

Fredun Pharmaceuticals Ltd has delivered its highest quarterly revenue and profit figures in the March 2026 quarter, signalling robust top-line growth despite emerging margin pressures and increased interest costs. The company’s financial trend has moderated from very positive to positive, reflecting a nuanced performance that investors should carefully analyse amid a recent downgrade in its Mojo Grade to Hold.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a new 52-week high of Rs 2620 on 25 May 2026, marking a remarkable 253.81% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained earnings growth, setting the stage for a compelling price rally within the pharmaceuticals sector.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,620 on 25 May 2026, reflecting a robust performance across multiple time frames and reaffirming its position as a strong player in the Pharmaceuticals & Biotechnology sector.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd reached a new 52-week high of Rs 2619.95 on 22 May 2026, marking a remarkable rally that has seen the stock gain over 250% in the past year. This milestone reflects a powerful confluence of technical momentum and sustained price strength, setting the stage for further market attention.

Extending its winning streak to four consecutive sessions, Fredun Pharmaceuticals Ltd surged to a fresh all-time high of Rs 2,619.95 on 22 May 2026, outperforming its sector and the broader market with a 1.81% gain on the day against the Sensex’s 0.46% rise.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd reached a fresh 52-week high of Rs 2560 on 21 May 2026, marking a remarkable rally from its 52-week low of Rs 690. This milestone caps a sustained upward momentum driven by a confluence of robust technical indicators and strong price action over recent sessions.

Fredun Pharmaceuticals Ltd has reached a new all-time high on 21 May 2026, closing at Rs 2,560.00, underscoring a remarkable phase of growth and market outperformance within the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 May 2026, providing investors with the latest insights into its performance and outlook.

With a remarkable surge to Rs 2550 on 11 May 2026, Fredun Pharmaceuticals Ltd has reached a new 52-week and all-time high, marking a spectacular 264.41% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained earnings growth, setting the stage for a compelling price rally despite broader market headwinds.